222 related articles for article (PubMed ID: 21735357)
41. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
42. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
43. [Trends in gastroenteropancreatic neuroendocrine tumors].
Kajiwara H; Osamura Y
Nihon Geka Gakkai Zasshi; 2008 May; 109(3):123-7. PubMed ID: 18536314
[TBL] [Abstract][Full Text] [Related]
44. [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Nold R; Frank M; Kajdan U; Trost U; Klose KJ; Arnold R
Z Gastroenterol; 1994 Apr; 32(4):193-7. PubMed ID: 7517086
[TBL] [Abstract][Full Text] [Related]
45. New developments in the treatment of gastrointestinal neuroendocrine tumors.
Kulke MH
Curr Oncol Rep; 2007 May; 9(3):177-83. PubMed ID: 17430688
[TBL] [Abstract][Full Text] [Related]
46. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
47. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
48. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
Strosberg JR; Cheema A; Kvols LK
Cancer Control; 2011 Apr; 18(2):127-37. PubMed ID: 21451455
[TBL] [Abstract][Full Text] [Related]
49. The safety of available treatments options for neuroendocrine tumors.
Faggiano A; Lo Calzo F; Pizza G; Modica R; Colao A
Expert Opin Drug Saf; 2017 Oct; 16(10):1149-1161. PubMed ID: 28705090
[TBL] [Abstract][Full Text] [Related]
50. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
51. Neuroendocrine tumors of the gastro-entero-pancreatic system.
Massironi S; Sciola V; Peracchi M; Ciafardini C; Spampatti MP; Conte D
World J Gastroenterol; 2008 Sep; 14(35):5377-84. PubMed ID: 18803349
[TBL] [Abstract][Full Text] [Related]
52. [Neuroendocrine tumours of the GI tract--data from the German NET Registry].
Begum N; Maasberg S; Plöckinger U; Anlauf M; Rinke A; Pöpperl G; Lehnert H; Izbicki JR; Krausch M; Vashist YK; Raffel A; Bürk CG; Hoffmann J; Goretzki P; Pape UF;
Zentralbl Chir; 2014 Jun; 139(3):276-83. PubMed ID: 23042103
[TBL] [Abstract][Full Text] [Related]
53. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
54. Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE).
Corleto VD; Panzuto F; Falconi M; Cannizzaro R; Angeletti S; Moretti A; Delle Fave G; Farinati F;
Dig Liver Dis; 2001 Apr; 33(3):217-21. PubMed ID: 11407665
[TBL] [Abstract][Full Text] [Related]
55. Neuroendocrine Tumors: Imaging of Treatment and Follow-up.
Migut AE; Kaur H; Avritscher R
Radiol Clin North Am; 2020 Nov; 58(6):1161-1171. PubMed ID: 33040855
[TBL] [Abstract][Full Text] [Related]
56. Gastrointestinal endocrine tumours: medical management.
Arnold R; Frank M
Baillieres Clin Gastroenterol; 1996 Dec; 10(4):737-59. PubMed ID: 9113320
[TBL] [Abstract][Full Text] [Related]
57. Advances in the treatment of neuroendocrine tumors.
Kulke M
Curr Treat Options Oncol; 2005 Sep; 6(5):397-409. PubMed ID: 16107243
[TBL] [Abstract][Full Text] [Related]
58. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
59. MicroRNAs and Treatment with Somatostatin Analogs in Gastro- Entero-Pancreatic Neuroendocrine Neoplasms: Challenges in Personalized Medicine.
Curt AM; Popa Ilie IR; Cainap C; Balacescu O; Ghervan C
J Gastrointestin Liver Dis; 2020 Dec; 29(4):647-659. PubMed ID: 33331339
[TBL] [Abstract][Full Text] [Related]
60. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies.
Schmidt C; Bloomston M; Shah MH
Oncogene; 2011 Mar; 30(13):1497-505. PubMed ID: 21132004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
